SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

3235-OMB Number:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

0104 Estimated average burden hours per 0.5 response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <u>Vida Ventures, LLC</u>	Requirir (Month/	2. Date of Event Requiring Statement (Month/Day/Year) 02/07/2024 3. Issuer Name and Ticker or Trading Symbol Kyverna Therapeutics, Inc. [KYTX]							
(Last) (First) (Middle) 40 BROAD STREET, SUITE 201 (Street)		2021	4. Relationship of Repo Issuer (Check all applicable) Director Officer (give title below)	orting P		ner	Filed	l (Month/Day/Y dividual or Joir ck Applicable Form filed b	nt/Group Filing
BOSTON MA 02109 (City) (State) (Zip)	_							Person	y More than One erson
Table I - Non-Derivative Securities Beneficially Owned									
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Ins 4)	ount of Securities 3. Own		rship 4. Nat irect Owne		ture of Indirect Beneficial ership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)	2. Date Exerce Expiration Da (Month/Day/)	ate	3. Title and Amount of Secur Underlying Derivative Securi 4)		urity (Instr. Conver or Exer		cise	cise Form:	6. Nature of Indirect Beneficial Ownership (Instr.
	Date Exercisable	Expiration Date	Title		unt or per of es	Price of Derivativ Security		Direct (D) or Indirect (I) (Instr. 5)	5)
Series A-1 Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	967,1 88 ⁽¹⁾		(1) D ⁽²⁾		D ⁽²⁾	
Series A-2 Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	1,940,388(1)		(1)		D ⁽²⁾	
Series B Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	1,616,348(1)		(1)		D ⁽²⁾	

Explanation of Responses:

1. The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.

2. Vida Ventures Advisors, LLC is the investment advisor to the Reporting Person. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by the Reporting Person, but each disclaims beneficial ownership of the shares held by the Reporting Person except to the extent of such person's pecuniary interest therein, if any.

Vida Ventures, LLC, By: /s/ Fred Cohen, Director	02/07/2024		
** Signature of Reporting	Date		

Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.